Good morning,
Welcome to today’s edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.
A few weeks ago, I asked for your feedback on the newsletter.
The overwhelming response?
More guest posts.
So I've been on the hunt for voices in the healthcare industry who can offer a different perspective and help you (and me) on our journey to become better healthcare investors.
The LinkedIn algorithm was locked in…
And someone kept popping up on my feed with short, sharp education videos on the medtech space that I genuinely found useful.
Danny Syring…
So I reached out.
Danny is a Senior Talent Director at FloodGate Medical, a firm that specialises in helping medtech companies build out their US sales forces.
(Basically, he’s a recruiter.)
I loved the videos.
So I asked if he'd be interested in sharing his experience with you, The Armchair Audience.
He was keen.
But what topic to cover…?
Given Danny's on-the-ground experience in the US, we landed on something that I think is poorly understood by ASX healthcare investors:
"How to evaluate a medtech’s US sales strategy as an everyday investor?"
There are quite a few high-profile ASX med tech companies that are at this stage right now:
4D Medical (4DX), Atrya (AYA), EchoIQ (EIQ), Cyclopharm (CYC), Orthocell (OCC), Tetratherix (TTX) and many more…
Specifically, Danny covers:
Getting to the starting gate: why FDA clearance and commercialisation are two very different things.
Choosing a go-to-market strategy: distribution partner vs direct sales team, and what the choice says about the company.
I was particularly interested in this one after my recent investment in Tetratherix (ASX: TTX).
The people behind the product: The key questions to ask management about who they're actually hiring to sell.
Once a product is FDA-cleared, the next question every investor asks is…
"When do you become profitable?"
There are many steps between approvals and profitability.
Knowing what to look for can be the difference between just backing a great science project OR backing a sustainable business.
Over to you Danny.
…
Hi, Danny Syring here, Senior Talent Director at FloodGate Medical.
The Armchair Analyst asked me to put together my experience on evaluating a medtech’s US sales strategy as an everyday investor.
So, here goes…
My company has spent the past 25 years helping medical device companies build commercial teams across every stage of the U.S. launch cycle.
What I’ve seen repeatedly is that the gap between ‘getting FDA cleared’ and ‘getting paid’ is far wider than most ASX investors appreciate.
The commercial decisions a company makes to bridge the gap between regulatory approval and commercial sustainability is what separates a scientific product from a great business.
So, here is my framework for evaluating and understanding where a medtech company is on the commercialisation pathway, and whether it is genuinely primed for success in the world’s most important medical device market: The USA.
(Not financial advice).
1. Getting a device approved does not equal getting paid.
This is the single most common miscalculation I see reflected in investor expectations.
Revenue doesn’t start flowing just because a device has been cleared by the FDA.
Clearance gives a company permission to sell. It does not mean hospitals or insurance will pay for the procedure or device.
There are two ways medical devices are paid: out of pocket or through reimbursement.
Reimbursement will be the primary way medical device companies get paid for their services, but before reimbursement flows reliably, three things typically need to happen.
(Each one generally takes longer and costs more money than the company expects)
First, CPT coding.
To get paid by the insurance companies, the device or procedure needs a billing code.
Applying for a new Category I CPT code through the AMA (the regulatory body that approves CPT Codes) takes two to three years.
Provisional Category III codes often reimburse at low or zero rates in the interim.
If the product fits an existing code (for example, a new cardiac monitor), the path is faster.
If it doesn’t, that timeline needs to be priced into expectations.
Second, Coverage decisions.
CMS (US Medicare) and private insurers each establish coverage policies independently.
Even with a code in place, companies may need to negotiate on a payer-by-payer basis, which can add another 12 to 24 months of variability before full-scale coverage.
Third, Hospital Value Analysis Committees.
Before a device is used routinely within a health system, it must pass an internal purchasing review.
These committees meet infrequently, move slowly, and require health economic data that early-stage companies rarely have ready at launch.
A company that clears the FDA in the first half of the year and projects meaningful revenue several months later is not accounting for this.
Questions to ask:
Did the company engage a reimbursement strategy before clearance, not after?
Is there an established CPT code?
Is there a reimbursement specialist on staff or retained?
These details signal commercial maturity and can matter more than the Total Addressable Market number that all medtech companies like to publish.
2. What is the go-to-market strategy: Distribution Partner or Direct Sales Force?
When a company chooses how to bring its product to market in the U.S., that decision reveals a lot about how well it understands its own selling environment.
Distributor Model
A distributor model uses independent reps who already have relationships with hospitals and physicians, carry multiple product lines, and don’t appear on the payroll.
For investors watching burn rate, it can look like capital discipline.
But most distributors prioritise their highest-earning, easiest-to-sell lines.
If the product requires physician education, procedural training, or a long sales cycle (and most disruptive medtech does), it will compete for attention within its own distribution network.
So, while distribution is more scalable, there needs to be direct alignment of incentives between the distributor and the sales rep.
Direct Sales Force
A direct sales force is costly, but can be effective if done right.
A strong U.S. territory rep, fully loaded with base, commission, car allowance, and benefits, runs US$180,000 to US$250,000 or more per year.
But direct reps carry one product. They own the relationships. They close the feedback loop back to clinical and marketing in a way distributors never do.
A few well-placed direct reps can outperform a nationwide distribution network that isn’t trained or incentivised to sell.
It’s the more expensive option, but it’s all a balance.
Cost vs Control.
Questions to ask:
Has management explained why they chose their model, not just what it is?
Does the choice match the product’s complexity and sales cycle?
A training-intensive device sold through a generalist distributor is a red flag - those products tend to sell best through a direct team… particularly before reimbursement is in place.
The best strategies start narrow and direct, with two or three priority markets, and scale with data behind them.
3. Is the company finding the right people to deliver its commercial strategy?
I’ve watched genuinely strong devices underperform commercially because of avoidable hiring and resourcing mistakes. Three patterns show up repeatedly.
Getting the first commercial leader right
The first VP of Sales or CCO sets the tone for everything that follows.
It’s all about finding the right fit.
A big-company executive from a mature medtech brand rarely thrives in an environment that demands scrappiness and the ability to build from scratch.
Whereas a career startup rep who has never managed a team at scale hits a ceiling fast.
The right profile is someone who has done it before at a company of similar size and complexity.
Those people are not easy to find or cheap to retain, which is exactly why this hire gets rushed or compromised.
Leveraging Customers as Champions
Physicians don’t just buy medtech products. They champion them, train on them, and publish data about them.
Companies that treat clinical and medical affairs as a cost centre to defer are asking their sales team to sell without air cover.
KOL (Key Opinion Leader) development, proctoring programs, and peer-reviewed data generation should not be overlooked as marketing overheads.
In most cases, they are the commercial strategy.
Distribution chosen to save money, not to drive adoption.
When the distribution model is selected on a spreadsheet rather than a commercial strategy, the result is predictable.
A product that sits in a bag alongside fifteen others, waiting for a rep who has no particular reason to prioritise it.
The company needs to answer the question “Why would the sales rep sell this?”.
5 Questions for any medtech company selling into the USA
Is there an established CPT code and a defined CMS coverage pathway? Does management understand the realistic timeline to reimbursement, not just the optimistic one?
Who, by name, is leading the commercial launch? Have they done this before at a company of comparable size and stage?
Is the go-to-market model a deliberate strategic fit for the product and its selling environment, or was it chosen primarily to manage burn rate?
Is there a funded medical affairs and KOL program, or is the sales team expected to carry the full commercial weight?
What does the first 12 months of U.S. revenue actually look like when reimbursement timelines are accounted for honestly?
A company that can answer these questions well is a strong signal that it has given its US go-to-market strategy deep consideration.
The U.S. remains the most valuable commercial market in the world for medical devices.
But the gap between an FDA-cleared product and a commercially successful business is real.
And it catches many investors off guard.
The companies that close that gap share a few common traits.
They understand reimbursement before they need it.
They hire commercial leaders who have navigated this specific environment before.
And they treat the go-to-market decision as strategy, not overhead management.
The ones that don’t tend to show up in your portfolio as a lesson learned.
Are you a medtech company developing a US go-to-market strategy?
Pay attention to this next bit…
Danny is Senior Talent Director at FloodGate Medical, a medtech talent strategy firm specialising in building commercial and functional teams for medical device companies across the U.S.
If you have any questions about a US go-to-market strategy for medical devices, reach out to Dannny here: [email protected].
Thanks, Danny, for that insight.
I just wanted to say that there is no commercial relationship between The Armchair Analyst and FloodGate Medical…
I honestly just like Danny’s videos and thought this content would be useful!
Now, how does this apply to Tetratherix (ASX: TTX)?
It’s clear. The best way for TTX to commercialise its technology across multiple (very different) product sets at once is…
The Distributor Model.
It’s a “deliberate strategic fit” for TTX’s incredibly versatile product.
Keeping costs low, and potential high.
Two products could be in the market this year, but as we’ve learned, that is just the starting gate.
TTX will work with its partners (who have been very strongly vetted) to put the product in the hands of a select group of strategic Key Opinion Leaders.
There is a deep strategic reason behind each product, each partner and each go-to-market strategy.
TTX is not just a platform in name only; the entire business model.
If you want to have a read of why I invested in TTX as well as my deep dive into the commercial strategy, read: My First Armchair Pick: Tetratherix (ASX: TTX)
See you all tomorrow,
The Armchair Analyst.
PS. Let me know if you liked this guest post, and I’ll look to do more!
But first…
The Pulse Check
InteliCare Holdings (ASX: ICR) appoints Angus Cameron as CEO. (ICR)
🪑 Momentum building here. A large deal with mecwacare last week and a new CEO this week. 30 years in the healthcare industry. 10 years at Phillips, nice hire.
Neurotech International (ASX: NTI) initiates the first clinical site at Monash Children's Hospital for its Phase 3 trial targeting core Autism Spectrum Disorder in 150 paediatric patients. (NTI)
🪑 A big trial starting is always good news. Note that this appears to be an Australian-only trial, as NTI has yet to obtain its IND in the US.
NeuroScientific Biopharmaceuticals (ASX:NSB) initiates technology transfer manufacturing run for its stem cell therapy process at Q-Gen in preparation for a Phase 2 trial in Crohn's Disease. (NSB)
Vitura Health (ASX: VIT) secures a binding distribution agreement with MedReleaf Australia, a Canadian producer of medical-grade cannabis products.
🪑“Vitura believes the agreement has the potential, over time, to contribute up to approximately $15 million in additional annual revenue.” But the terms have “no minimum purchase or volume commitments”.
Wonder how they came up with that number?
Clarity Pharmaceuticals (ASX: CU6) Co-PSMA trial results showing superior diagnostic performance between its product and Telix’s product were published in the journal European Urology and presented at the EAU Congress 2026. (CU6)
China’s Neuracle Technology receives world-first approval for a brain-computer interface system treating spinal cord injuries. (Fierece Pharma)
Tetratherix (ASX: TTX) also presented to the market today, with additional information on its new platform and its deal with Superpower. (TTX)
🪑I watched the whole thing so that you didn’t have to.
My takeaways
Technology is super modular: Transparent or opaque, lasts 5 minutes or 12 weeks, compatible with a bunch of human tissue. The perfect “platform” technology.
Everything in the company is done in a “capital-light” way, from the go-to-market strategy to the R&D.
There is a LOT of science behind the nasal spray technology. 5 years of research went into developing this.
The decision to partner this tech with Big Pharma or Superpower was an interesting one. TTX chose Superpower because they could move much faster to get it into patients' hands.
Will’s answer to the question “Where is the orthopedic partnership?” was very good. He explained that he is looking to make “the right decision, not the quick one”. Partner to be chosen soon.
More TTX in the media:
But first…
The Pulse Check
InteliCare Holdings (ASX: ICR) appoints Angus Cameron as CEO. (ICR)
🪑 Momentum building here. A large deal with mecwacare last week and a new CEO this week. 30 years in the healthcare industry. 10 years at Phillips, nice hire.
Neurotech International (ASX: NTI) initiates the first clinical site at Monash Children's Hospital for its Phase 3 trial targeting core Autism Spectrum Disorder in 150 paediatric patients. (NTI)
🪑 A big trial starting is always good news. Note that this appears to be an Australian-only trial, as NTI has yet to obtain its IND in the US.
NeuroScientific Biopharmaceuticals (ASX:NSB) initiates technology transfer manufacturing run for its stem cell therapy process at Q-Gen in preparation for a Phase 2 trial in Crohn's Disease. (NSB)
Vitura Health (ASX: VIT) secures a binding distribution agreement with MedReleaf Australia, a Canadian producer of medical-grade cannabis products.
🪑“Vitura believes the agreement has the potential, over time, to contribute up to approximately $15 million in additional annual revenue.” But the terms have “no minimum purchase or volume commitments”.
Wonder how they came up with that number?
Clarity Pharmaceuticals (ASX: CU6) Co-PSMA trial results showing superior diagnostic performance between its product and Telix’s product were published in the journal European Urology and presented at the EAU Congress 2026. (CU6)
China’s Neuracle Technology receives world-first approval for a brain-computer interface system treating spinal cord injuries. (Fierece Pharma)
Tetratherix (ASX: TTX) also presented to the market today, with additional information on its new platform and its deal with Superpower. (TTX)
🪑I watched the whole thing so that you didn’t have to.
My takeaways
Technology is super modular: Transparent or opaque, lasts 5 minutes or 12 weeks, compatible with a bunch of human tissue. The perfect “platform” technology.
Everything in the company is done in a “capital-light” way, from the go-to-market strategy to the R&D.
There is a LOT of science behind the nasal spray technology. 5 years of research went into developing this.
The decision to partner this tech with Big Pharma or Superpower was an interesting one. TTX chose Superpower because they could move much faster to get it into patients' hands.
Will’s answer to the question “Where is the orthopedic partnership?” was very good. He explained that he is looking to make “the right decision, not the quick one”. Partner to be chosen soon.
More TTX in the media:
Cash Injection
Argenica Therapeutics (ASX: AGN) receives a $3.97M R&D tax rebate for FY25. (AGN)
